Should I stop taking duloxetine immediately?

No. The FDA and Breckenridge both advise patients not to stop taking duloxetine on their own, even if their bottle matches a recalled lot. Stopping duloxetine abruptly can cause discontinuation symptoms such as dizziness, nausea, irritability, and electric-shock-like sensations. Contact your doctor or pharmacist first to arrange a replacement or an alternative medication.

How do I check my lot number?

Look at the prescription label on your pill bottle for the lot number (sometimes labeled 'LOT' or 'Batch') and expiration date, then compare them against the recalled lots listed in the FDA's enforcement report or your pharmacy's recall notice. Because Breckenridge has issued this recall in phases, the safest step is to call your pharmacy directly and read them your lot number rather than relying solely on any single list, including this one.

What medications can I switch to?

Your doctor may consider other SNRIs such as venlafaxine or desvenlafaxine, or an unaffected duloxetine manufacturer's lot, depending on your diagnosis and history. Switching antidepressants requires an individualized plan from your prescriber, since dosing is not directly interchangeable between these medications.

Will my pharmacy replace recalled duloxetine for free?

Most pharmacies will exchange a recalled bottle for an unaffected lot or a different manufacturer's duloxetine at no additional cost, since the recall is not the patient's fault. Breckenridge has also established a refund program for patients who purchased recalled duloxetine and want reimbursement for unused or returned product from recalls issued after May 22, 2025.

Is generic duloxetine also recalled?

This recall specifically affects generic duloxetine capsules manufactured by Towa Pharmaceutical Europe and distributed in the U.S. by Breckenridge Pharmaceutical. Duloxetine made by other generic manufacturers, and brand-name Cymbalta, are not part of this particular recall. Check the manufacturer name printed on your pharmacy label or bottle to confirm which company made your specific prescription.

Duloxetine (Cymbalta) Recall 2026: Check Your Lot Number

Drug Safety Notice: This guide reflects the Breckenridge Pharmaceutical duloxetine recall as reported through July 11, 2026. Recall lot lists can be updated, so always verify your specific bottle against the FDA's official enforcement report or by calling your pharmacy directly — do not rely on any single article for a final answer.

Quick Answer

Breckenridge Pharmaceutical has recalled roughly 375,000 bottles of generic duloxetine delayed-release capsules (14,729 bottles of 30 mg and 359,676 bottles of 60 mg) after testing found the impurity N-nitroso-duloxetine — a nitrosamine compound — above the FDA's acceptable limit. This is a Class II recall, meaning the FDA considers serious harm unlikely, and it's the 14th nitrosamine-related recall event Breckenridge has issued for duloxetine since 2024. Do not stop taking duloxetine on your own — contact your doctor or pharmacist to check your lot number and arrange a replacement. This recall affects Breckenridge-distributed generic duloxetine only, manufactured by Towa Pharmaceutical Europe — not all duloxetine, and not brand-name Cymbalta.

Key Takeaways

Don't stop cold turkey: Stopping duloxetine abruptly can cause withdrawal-like discontinuation symptoms — talk to your doctor first.
~375,000 bottles recalled across specific 30 mg and 60 mg lots, distributed nationwide.
Class II recall: the FDA considers the immediate health risk low, but long-term nitrosamine exposure above safe limits is linked to elevated cancer risk in animal studies.
This is a pattern, not a one-off: it's Breckenridge's 14th duloxetine nitrosamine recall since 2024 — worth discussing with your pharmacist even beyond this specific event.
A refund program exists for patients who already used or discarded recalled Breckenridge duloxetine purchased after May 22, 2025.

If you take duloxetine for depression, anxiety, or nerve pain, you may have seen headlines in June 2026 about a recall of the generic version. Here's what's actually going on, whether your specific bottle is affected, and exactly what to do next — without the panic or the bureaucratic jargon.

1. What Happened: The Recall in Plain English

Breckenridge Pharmaceutical, Inc. initiated a voluntary retail-level recall of specific lots of duloxetine delayed-release capsules after laboratory testing found elevated levels of N-nitroso-duloxetine, a nitrosamine drug substance-related impurity (NDSRI), above the FDA's proposed interim safety limit. The capsules were manufactured by Towa Pharmaceutical Europe, S.L. in Martorelles (Barcelona), Spain, and distributed nationwide in the U.S. by Breckenridge.

~375,000

total bottles recalled (14,729 × 30 mg + 359,676 × 60 mg)

Class II

FDA recall classification — limited acute risk

14th

Breckenridge duloxetine nitrosamine recall event since 2024

News coverage of this recall accelerated in mid-June 2026, after outlets including ABC News and NBC New York reported on the FDA's enforcement listing. Breckenridge has stated it is not aware of any adverse events that have been assessed as related to this specific recall.

2. Check Your Bottle: Reported Lot Numbers

Find these three things on your prescription label before calling anyone:

The manufacturer name — this recall only applies to Breckenridge Pharmaceutical duloxetine
The strength — 30 mg or 60 mg
The lot number (sometimes labeled "LOT" or "Batch #") and expiration date

Lot numbers reported for this recall (verify against the FDA enforcement report or your pharmacy)
Strength	Lot Number	Expiration Date
30 mg	241180C	April 2027
60 mg	230286C	February 2026
60 mg	240721C	February 2027

Important: this list may not be complete. Because Breckenridge has issued duloxetine nitrosamine recalls repeatedly — 14 times since 2024, according to industry drug-safety trackers — additional lots beyond those reported here may also be affected. Lot numbers reported in news coverage can also be transcribed inconsistently between outlets. Do not treat this table as the final word. Always cross-check your specific lot number against the FDA's official enforcement report or call your pharmacy and read them the lot number directly from your bottle.

3. What Are Nitrosamines? (Without the Fear-Mongering)

Nitrosamines are chemical compounds that can form during a drug's manufacturing, synthesis, or storage process — they're not something added on purpose, and they're not unique to duloxetine. Since 2018, nitrosamine-related recalls have affected numerous widely used generic medications, including valsartan, ranitidine, and metformin. Duloxetine's chemical structure includes a secondary amine group, which regulators have flagged as structurally susceptible to this type of impurity forming during production.

What the FDA actually says: Nitrosamines "may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time." Critically, the agency also states that exposure at or below its acceptable daily intake limit is not expected to meaningfully increase a patient's cancer risk. There is no data linking N-nitroso-duloxetine specifically to confirmed human cancer cases — the concern is based on the compound's chemical classification and animal study data, not confirmed clinical harm at the levels found in this recall.

4. Should You Stop Taking Duloxetine?

No — not without talking to your doctor first. Duloxetine, like other SNRIs, can cause discontinuation symptoms if stopped abruptly, including dizziness, nausea, irritability, flu-like symptoms, and "brain zap" sensations. The FDA and Breckenridge both explicitly advise patients not to change their treatment on their own just because a product has been recalled. Even if your bottle matches a recalled lot, the priority is getting a safe replacement — not going without medication.

5. Step-by-Step: What to Do Right Now

Keep taking your current dose

Continue your prescribed duloxetine while you sort out whether your bottle is affected — don't pause or skip doses on your own.

Find your manufacturer, strength, and lot number

Check the pharmacy label on your bottle. If the manufacturer isn't Breckenridge Pharmaceutical, this specific recall doesn't apply to your prescription — but ask your pharmacist to confirm.

Call your pharmacy to verify

Read your exact lot number to your pharmacist. Pharmacies receive official recall notices directly and can confirm with certainty whether your specific bottle is included.

Get a replacement, not a refusal

If your lot is affected, ask your pharmacy to exchange it for an unaffected Breckenridge lot or a different manufacturer's duloxetine — most pharmacies will do this at no additional cost since the recall isn't the patient's fault.

Ask about the refund program if you already finished the bottle

Breckenridge has established a refund program covering out-of-pocket costs for unused or returned duloxetine tied to recalls issued after May 22, 2025. Ask your pharmacist how to file a claim, or check the FDA enforcement report for current program details.

6. Script: What to Say to Your Pharmacist or Doctor

If picking up the phone feels daunting, here's exactly what to say:

To your pharmacist

"Hi, I take duloxetine and I saw there's a 2026 recall from Breckenridge Pharmaceutical. My bottle's lot number is [read your lot number]. Can you check whether this specific lot is recalled, and if so, can you swap it for an unaffected lot or a different manufacturer at no charge?"

To your doctor's office

"My duloxetine may be part of the Breckenridge recall. I don't want to stop taking it without guidance — can you confirm whether I should continue on the same medication once my pharmacy replaces it, or whether we should consider an alternative?"

7. If You Need an Alternative: Options to Discuss With Your Doctor

In most cases, simply swapping to an unaffected lot or a different manufacturer's duloxetine solves the problem without changing medications at all. But if a replacement isn't readily available, or your doctor has other reasons to consider a change, these are other SNRIs sometimes discussed as alternatives — only your prescriber can determine if one is appropriate for you, since dosing is not directly interchangeable between these medications:

Other SNRIs sometimes discussed as alternatives (for your doctor's evaluation only)
Medication	Drug class	Typically prescribed for
Venlafaxine (generic Effexor XR)	SNRI	Depression, generalized anxiety disorder
Desvenlafaxine (generic Pristiq)	SNRI	Major depressive disorder
Milnacipran (Savella)	SNRI	Fibromyalgia (not FDA-approved for depression in the U.S.)

Cash prices for generic SNRIs like venlafaxine and desvenlafaxine are typically in the low-cost generic tier at most pharmacies with a discount card, though exact pricing varies by pharmacy, location, and dose. Compare current prices using GoodRx or a drug price checker before assuming any switch will change your out-of-pocket cost.

8. What If Your Pharmacy Is Out of Stock?

Recalls affecting a major generic manufacturer can create temporary local shortages while pharmacies restock from unaffected lots or other manufacturers. If your usual pharmacy is out:

Ask if they can check inventory at a nearby location within the same chain.
Ask your doctor if a short bridge supply or temporary alternative is appropriate while you wait.
Check whether your insurance requires a specific manufacturer, or whether any FDA-approved generic duloxetine is acceptable under your plan.

People Also Ask (FAQ)

No. The FDA and Breckenridge both advise against stopping duloxetine on your own, even if your bottle matches a recalled lot. Stopping abruptly can cause discontinuation symptoms like dizziness, nausea, irritability, and "brain zap" sensations. Contact your doctor or pharmacist first to arrange a replacement.

Nitrosamines are compounds that can form during a drug's manufacturing, storage, or packaging. Some are classified as probable human carcinogens based on animal studies, meaning long-term exposure above acceptable limits may raise cancer risk over time. The FDA states that exposure at or below its acceptable daily intake limit is not expected to meaningfully increase cancer risk, and there are no confirmed human cancer cases linked specifically to this recall.

Look at your prescription label for the lot number and expiration date, then compare it against the FDA's enforcement report or call your pharmacy directly. Because this recall has rolled out in phases, verifying with your pharmacist is more reliable than relying on any single published list.

Your doctor may consider other SNRIs like venlafaxine or desvenlafaxine, or simply switching to an unaffected duloxetine lot or manufacturer. Any switch should be individualized by your prescriber, since dosing isn't directly interchangeable between these medications.

Most pharmacies will exchange a recalled bottle for an unaffected lot or different manufacturer at no additional cost. Breckenridge has also set up a refund program for patients seeking reimbursement for unused or returned duloxetine tied to recalls issued after May 22, 2025.

This recall specifically covers generic duloxetine manufactured by Towa Pharmaceutical Europe and distributed by Breckenridge Pharmaceutical. Duloxetine from other generic manufacturers, and brand-name Cymbalta, are not part of this particular recall — check the manufacturer name on your label to confirm.

Disclaimer: This guide is for general educational purposes and reflects recall reporting as of July 11, 2026. It is not a substitute for advice from your doctor, pharmacist, or the FDA. Lot numbers and recall scope can be updated by the manufacturer or FDA — always verify your specific medication against the official FDA enforcement report or your pharmacy before making any decisions. Sources: FDA Enforcement Report, Breckenridge Pharmaceutical recall notices, California State Board of Pharmacy, ABC News, NBC New York, Pharmaceutical Technology, and MedShadow Foundation.

About the Author

Evan Brown — Medical Content Researcher

Evan Brown is a medical content researcher who specializes in translating complex drug safety and recall information into clear, actionable guidance for patients.

View Full Profile →

Medical Review

Dr. Megan Harris, MD

Dr. Megan Harris, MD reviews health content for medical accuracy, checking drug safety information and recall details against current FDA and manufacturer sources.